Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

This study has suspended participant recruitment.
(Determining evaluable subjects)
Sponsor:
Collaborator:
Seattle Genetics, Inc.
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01578967
First received: April 13, 2012
Last updated: February 3, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: January 2018
  Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)